Literature DB >> 21102267

Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation.

Yao-Wen Kuo1, Shang-Gin Wu, Chao-Chi Ho, Jin-Yuan Shih.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21102267     DOI： 10.1097/JTO.0b013e3181f43274

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  35 in total

1.  Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors.

Authors:  F Koinis; A Voutsina; A Kalikaki; A Koutsopoulos; E Lagoudaki; E Tsakalaki; E K Dermitzaki; E Kontopodis; A G Pallis; V Georgoulias; A Kotsakis
Journal:  Clin Transl Oncol       Date:  2017-06-19       Impact factor: 3.405

2.  Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.

Authors:  Yiming Zhao; Shuyuan Wang; Bo Zhang; Rong Qiao; Jianlin Xu; Lele Zhang; Yanwei Zhang; Baohui Han
Journal:  Target Oncol       Date:  2019-04       Impact factor: 4.493

3.  CRISPR-barcoding in non small cell lung cancer: from intratumor genetic heterogeneity modeling to cancer therapy application.

Authors:  Federica Zito Marino; Marina Accardo; Renato Franco
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

4.  Immunohistochemistry reliably detects ALK rearrangements in patients with advanced non-small-cell lung cancer.

Authors:  Xiao-Hong Han; Ning-Ning Zhang; Li Ma; Dong-Mei Lin; Xue-Zhi Hao; Yu-Tao Liu; Lin Wang; Peng Liu; Zheng Yuan; Dan Li; Hua Lin; Yan Sun; Yuan-Kai Shi
Journal:  Virchows Arch       Date:  2013-08-18       Impact factor: 4.064

5.  Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Authors:  Robert C Doebele; Amanda B Pilling; Dara L Aisner; Tatiana G Kutateladze; Anh T Le; Andrew J Weickhardt; Kimi L Kondo; Derek J Linderman; Lynn E Heasley; Wilbur A Franklin; Marileila Varella-Garcia; D Ross Camidge
Journal:  Clin Cancer Res       Date:  2012-01-10       Impact factor: 12.531

Review 6.  Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.

Authors:  Sai-Hong Ignatius Ou; Cynthia Huang Bartlett; Mari Mino-Kenudson; Jean Cui; A John Iafrate
Journal:  Oncologist       Date:  2012-09-18

7.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  J Thorac Oncol       Date:  2013-07       Impact factor: 15.609

8.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  Arch Pathol Lab Med       Date:  2013-04-03       Impact factor: 5.534

9.  ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.

Authors:  Justin F Gainor; Anna M Varghese; Sai-Hong Ignatius Ou; Sheheryar Kabraji; Mark M Awad; Ryohei Katayama; Amanda Pawlak; Mari Mino-Kenudson; Beow Y Yeap; Gregory J Riely; A John Iafrate; Maria E Arcila; Marc Ladanyi; Jeffrey A Engelman; Dora Dias-Santagata; Alice T Shaw
Journal:  Clin Cancer Res       Date:  2013-05-31       Impact factor: 12.531

10.  Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation coexisting in Chinese patients with lung adenocarcinoma.

Authors:  Jianfei Zhu; Ling Cai; Haoxian Yang; Yinsheng Wen; Junye Wang; Tiehua Rong; Jianyong Shao; Lanjun Zhang
Journal:  Thorac Cancer       Date:  2014-08-25       Impact factor: 3.500
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.